Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations
Status:
Recruiting
Trial end date:
2021-09-01
Target enrollment:
Participant gender:
Summary
This study will attempt to determine the efficacy of checkpoint inhibitor immunotherapy with
nivolumab and ipilimumab combination therapy followed by nivolumab monotherapy in patients
with metastatic prostate cancer harboring loss of CDK12 function.
Phase:
Phase 2
Details
Lead Sponsor:
University of Michigan Cancer Center University of Michigan Rogel Cancer Center
Collaborators:
Memorial Sloan Kettering Cancer Center University of California, San Francisco